MindMed appoints new VP of R&D Strategy By Investing.com
NEW YORK – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a biopharmaceutical company focusing on brain health disorders, announced today the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. Dr. Muniz brings extensive experience from his time at the U.S. Food and Drug Administration (FDA) and his service in the uniformed services, including roles in neuroscience and psychiatry.
In his new position, Dr. Muniz is expected to spearhead the innovation and expansion of MindMed’s R&D operations. The company is preparing for three Phase 3 studies of its MM120 orally disintegrating tablet (ODT) for the treatment of generalized anxiety disorder and major depressive disorder. Dr. Muniz’s…
